Two-stage design and 'forced bioequivalence' [Two-Stage / GS Designs]

posted by Yura – Belarus, 2018-06-07 10:24 (957 d 21:42 ago) – Posting: # 18859
Views: 3,231

Hi Mikalai,
'forced bioequivalence' - it's not from "that opera".
If you took for 2х2х2 n = 120 for CL AUCt (90-111.11 - with narrow therapeutic index), CV = 16.5% and recommended GMR = 97.5%, while in calculation (in R) for 2х2х4 you get n = 30.
The sample size is twice as high as possible, which is not ethical - to expose an unknown effect of the test drug to more people than necessary.
If I understand correctly, that's it 'forced bioequivalence'

Complete thread:

 Admin contact
21,306 posts in 4,443 threads, 1,489 registered users;
online 6 (0 registered, 6 guests [including 4 identified bots]).
Forum time: Wednesday 07:06 CET (Europe/Vienna)

Power: That which is wielded by the priesthood of
clinical trials, the statisticians, and a stick which they use
to beta their colleagues.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz